MARATTO

review · ecancermedicalscience

Assessment of treatment plans from high-dose-rate-brachytherapy of prostate cancer in Nigeria: findings from pioneer centre

Abstract

Introduction: High dose rate (HDR) brachytherapy is a promising therapeutic approach for localised prostate cancer. Optimised treatment plans have been shown to improve disease control and reduce toxicity on the organs-at-risk (OAR). Aim: To report findings from the treatment plan parameters (TPPs) obtained from two different HDR brachytherapy treatment regimens at the University College Hospital, Ibadan Nigeria. Methods: The treatment plans of 90 patients, who had HDR brachytherapy to the prostate gland between August 2020 and October 2023 were considered. All were treated with Bebig Saginova machine, housing Cobalt-60 source, the first multi-channel unit in the country then. 44% of patients received dose of 18 Gy in 2 fractions (category A), while the remaining received 27 Gy in 2 fractions (category B). Treatment plans were generated on the Sagiplan 2.0 treatment planning system from Eckert & Ziegler, BEBIG and relevant TPP were extracted and analysed using IBM SPSS 27. Results: and PVol. in both categories. Conclusion: Although, some level of optimal dose coverage around the prostate gland was achieved for some of the patients, especially those in Category B, there is still room for improvement to minimise the dose to OAR.

Research topics

  • Prostate Cancer Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Advances in Oncology and Radiotherapy

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3332/ecancer.2025.1906

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.